Skip to main content
Premium Trial:

Request an Annual Quote

Between Funding and IRBs, It's a Wonder Anyone Researches Us at All

Normally we don't link back to items more than a week old, but GTO missed the boat on this column in the last issue of Newsweek and it's worth a read. Sharon Begley writes about the challenges of translational research -- starting with the difficulty in getting grant funding compared to basic research projects. "That's what clinical scientists, who feel like the stepchildren of biomedical research compared with the cool kids who study fruit flies, have long suspected, and last month brought quantitative proof," she writes. A study of NIH grant proposals from 2000 to 2004 "found that those for research with people got much lower scores, and thus were less likely to be funded, than those for research on cell cultures, animals and the like." Begley's column also touches on why more scientists are avoiding the red tape involved with research that would necessitate dealing with an IRB.

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.